FORMULATION ARTICLES
-
Unlocking Established Immunological Pathways: How mRNA And LNP Technologies Can Reshape Cancer Therapy
The latest generation of LNP technologies holds the promise of delivering therapies to precise cells and tissues outside the liver, while mRNA technology allows transient protein expression to be maintained.
-
Comparing Advanced Modality Needs, Part 1: Manufacturing
ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.
-
4 Delivery Science Lessons For RNA Developers
Drawing on published science, current guidance, and the author's own perspective, four delivery science lessons become clear for RNA developers.
-
Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions
This last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.
-
Protecting The Platform: Trade Secret Protection For RNA Biotech Companies
As RNA therapeutics grow more complex and collaborative, trade secrets are becoming an increasingly important part of protecting valuable platform innovation.
-
How Should We Measure The True Potency Of RNA Therapeutics?
An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Explore how a standardized cryopreservation process is transforming leukapheresis handling by reducing risk and improving quality across the cell therapy supply chain.
-
Advancements in purification, delivery mechanisms, and stability during storage and transport will enable the future of mRNA-based therapies.
-
Monoclonal antibodies (mAbs) stand as pivotal drug products and biochemical reagents in the 21st century. Explore how mRNA-encoded antigens could revolutionize antibody discovery.
-
With adjustable components and increased stability during bloodstream circulation, LNPs are significantly advancing drug development and delivery, particularly for mRNA vaccines.
-
Optimizing LNPs for in vivo CAR-T requires aligning target selection, formulation design, and delivery performance to achieve functional CAR expression in desired T-cell populations while balancing specificity, safety, dosing flexibility, and manufacturability.
-
Cryopreservation eliminates rigid timelines by decoupling collection from production, providing the flexibility needed to optimize facility use and stabilize advanced therapy supply chains.
-
Learn about an HPLC-MS/MS method for detecting lipid impurities in lipid nanoparticles (LNPs) and why it is critical for quality control of LNP-based drug delivery systems.